ArticleEuropean journal of case reports in internal medicine2025
Gliclazide Challenge Testing as an Alternative Diagnostic Tool for Hepatocyte Nuclear Factor-1-Alpha Maturity Onset Diabetes of the Young.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocyte nuclear factor-1-alpha monogenic diabetes (HNF1-alpha DM), formerly known as maturity-onset diabetes of the young type 3 (MODY 3), is often misdiagnosed as type 1 or type 2 diabetes. In regions where genetic testing is unavailable, alternative diagnostic approaches are needed. Case report: A 20-year-old woman was initially diagnosed with type 1 diabetes after an incidental finding of hyperglycaemia. Despite adherence to treatment, she experienced recurrent hypoglycaemia on basal-bolus insulin, receiving over 2600 injections in 8 years. Autoantibodies were negative, C-peptide levels were preserved, and her estimated probability of MODY exceeded 10%. While awaiting genetic testing, she underwent a "glicazide challenge test", which showed a marked stimulatory response in blood glucose and C-peptide levels. Subsequent testing confirmed HNF1-alpha MODY. Insulin was stopped, and she was started on low dose gliclazide, achieving excellent control with minimal hypoglycaemia. Conclusion: This case demonstrates the gliclazide challenge test's potential as an alternative diagnostic and therapeutic tool in suspected maturity-onset diabetes of the young when genetic testing is limited. LEARNING POINTS: Young patients with atypical diabetes (negative autoantibodies, preserved C-peptide, recurrent hypoglycaemia on insulin) should prompt consideration of monogenic diabetes, and the Exeter maturity-onset diabetes of the young calculator is a valuable screening tool for clinicians.A gliclazide challenge test with serial C-peptide measurement can provide a simple, functional assessment of sulfonylurea sensitivity, supporting the diagnosis of maturity-onset diabetes of the young, in centres where genetic testing is limited or delayed.Early recognition of maturity-onset diabetes of the young allows safe transition from insulin to sulfonylureas, preventing years of unnecessary injections, reducing hypoglycaemic episodes, and improving long-term quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.